# OnCo record admec-o (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/admec-o/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "admec-o", "NCT02196961" ;
  schema:name "ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)"@en ;
  schema:alternateName "ADMEC-O"@en, "ADMEC"@en ;
  schema:description "Merkel cell carcinoma comes back in a quarter of people even after the surgeon has removed it all. Giving immunotherapy afterwards for a year reduced that by about ten in every hundred, but the trial was small and cannot yet say whether anyone lived longer."@en ;
  schema:url <https://onco.cc/trials/admec-o/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02196961>, <https://doi.org/10.1016/S0140-6736(23)00769-9>, <https://pubmed.ncbi.nlm.nih.gov/37451295/>, <https://doi.org/10.1016/S0140-6736(23)01041-3> ;
  onco:status "mixed" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/merkel-cell-carcinoma/>, <https://onco.cc/cancers/skin-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/irae/>, <https://onco.cc/terms/mcpyv-status/> ;
  onco:trials <https://onco.cc/trials/stamp-merkel/>, <https://onco.cc/trials/javelin-merkel-200/>, <https://onco.cc/trials/keynote-017/>, <https://onco.cc/trials/pod1um-201/> .